Activity Preview

Live

Treating Co-Occurring Depression and Opioid Use Disorder: A Case Discussion (Archived Webinar)

Activity Type:

  • On Demand


Release Date: 10/27/2015

Expiration Date: 12/31/2020

  • AMA PRA Category 1: 1
  • Participation: 1

Register

Description

Depression co-occurs frequently with opioid use disorder, with past-year prevalence estimates of 25% for major depressive disorder and higher estimates for lifetime major depressive disorder. Despite high rates of co-occurrence, little information is available from controlled clinical trials to guide treatment of this population. This webinar will review key information from epidemiological studies, secondary analyses of controlled trials, and naturalistic data/case reports that may inform clinicians about patient care strategies. Ways in which current symptoms of depression or suicidality may affect patient engagement in treatment will be considered along with strategies to prevent opioid overdose and suicide. Opioidergic neurobiology as it pertains to current hypotheses related to antidepressant response in animal models and human trials will be briefly considered in the context of considering agonist replacement therapies in patients with co-occurring depression and opioid use disorder. Models to provide integrated care for opioid use disorder and depression will be discussed.

Funding for this initiative was made possible (in part) by grant no. 5U79TI026556-03 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. pcssnow.org

Pricing

  • General Member - Free
  • Resident-Fellow Member - Free
  • Medical Student Member - Free
  • Non-Member - Free

Educational Objectives

  • Review what is currently known about the prevalence of co-occurring opioid use disorder and depression and the clinical care of these patients
  • Review hypotheses on opioidergic neurobiology as potential neurotherapeutic targets in depression and consider implications for opioid agonist treatment of co-occurring opioid use disorder and depression 
  • Discuss important gaps in the evidence base and empirical models of integrating care of opioid use disorder and depression

Target Audience

Physicians who have a waiver to treat opioid dependence in an office-based setting and other interested clinicians

Estimated Time to Complete

Estimated Duration: 1 Hour
Program Begin Date: October 27, 2015
Program Review Date: November 1, 2018
Program End Date: December 31, 2020

How to Earn Credit

Participants who wish to earn AMA PRA Category 1 Credit ™ or a certificate of participation may do so by completing all sections of the course including the evaluation. A multiple choice quiz is provided based on the content. A passing score of 60% must be achieved. Retakes are available for the test. After evaluating the program, course participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians) or certificate of participation (non-physicians) showing the date of completion and hours earned. 

Continuing Education Credit

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this enduring CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Planner Disclosures

Faculty

  • Hilary Smith Connery, M.D., Ph.D., Clinical Director, Alcohol and Drug Abuse Treatment Program, Mclean Hospital, Assistant Professor of Psychiatry, Harvard Medical School. Reports no financial relationships with commercial interests.

Program Planners

  • Andrew Saxon, M.D., Professor, Department of Psychiatry & Behavioral Sciences; Director, Addiction Psychiatry Residency Program, University of Washington; Director, Center of Excellence in Substance Abuse Treatment and Education (CESATE) VA Puget Sound Health Care System. Reports no financial relationships with commercial interests.
  • Beatrice Eld, Associate Director, Addiction Psychiatry, American Psychiatric Association. Reports no financial relationships with commercial interests
  • John A. Renner, Jr., M.D., Boston University School of Medicine, Director, Addiction Psychiatry Residency Training, Boston University Medical Center and VA Boston Healthcare System. Disclosure: Stock/other financial options: Johnson & Johnson and General Electric.
  • Frances R. Levin, M.D., Kennedy Leavy Professor of Psychiatry at Columbia University Medical Center; Director, Addiction Psychiatry Fellowship, New York Presbyterian Hospital; Director of Clinical and Educational Activities for the Division on Substance Abuse, New York State Psychiatric Institute. Disclosure: Consultant: Major League Baseball, Grant/Research Support: US World Med.

Program Reviewer

  • John A. Renner, Jr., M.D., Boston University School of Medicine, Director, Addiction Psychiatry Residency Training, Boston University Medical Center and VA Boston Healthcare System. Disclosure: Stock/other financial options: Johnson & Johnson and General Electric.

Hardware/Software Requirements

This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration:

  • Flash Player: Adobe Flash Player 10.1+ 
  • Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+ 
  • Operating System: Windows XP+ or Mac OS X 10.4+ 
  • Internet Connection: 1 Mbps or higher

Minimum Requirements:

Windows PC:
500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera

Macintosh:
Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit

For assistance: Contact pcssmat@psych.org for questions about this course | Contact learningcenter@psych.org for technical assistance

Register